Your session is about to expire
← Back to Search
Device
MST for Parkinson's Disease (MST-PD Trial)
N/A
Waitlist Available
Led By Fidel Vila-Rodriguez, MD, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
≥50 years old
Confirmed diagnosis of Parkinson's disease based on UK Brain Bank criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights
MST-PD Trial Summary
This trial is testing whether a new therapy, Magnetic Seizure Therapy, is effective in treating depression in patients with Parkinson's Disease.
Eligible Conditions
- Parkinson's Disease
- Movement Disorders
- Depression
MST-PD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
You are 50 years of age or older.
Select...
You have been diagnosed with Parkinson's disease using specific criteria from the UK Brain Bank.
Select...
You have Parkinson's disease at a moderate stage.
Select...
You have been diagnosed with a current major depressive episode using the MINI International Neuropsychiatric Interview, Version 6.
Select...
You have a score of 22 or higher on a test that measures how severe your depression is.
Select...
You are approved by a psychiatrist and an anaesthesiologist to receive convulsive therapy.
Select...
If you are taking antidepressant medication, you must be willing to continue taking the same medication during the study.
Select...
Meet the safety criteria for the study.
MST-PD Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: recruitment
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: retention
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: side effects
Secondary outcome measures
Efficacy information to plan future definite trial
MST-PD Trial Design
1Treatment groups
Experimental Treatment
Group I: Magnetic Seizure TherapyExperimental Treatment1 Intervention
MST treatments will be administered using the MagPro XP MST with Cool TwinCoil.
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,407 Previous Clinical Trials
1,766,529 Total Patients Enrolled
Fidel Vila-Rodriguez, MD, PhDPrincipal InvestigatorUniversity of British Columbia
2 Previous Clinical Trials
520 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have any of the heart-related risk factors mentioned in the Revised Cardiac Risk Index Score.You started taking certain types of medications for mental health less than 4 weeks ago.You are 50 years of age or older.You are currently experiencing severe mental health issues that affect your thoughts and behaviors.You have a metal object in or near your head that can't be safely taken out.You are taking a high dose of a medication called benzodiazepine or anticonvulsants, which may affect the effectiveness of the study treatment.You have been diagnosed with Parkinson's disease using specific criteria from the UK Brain Bank.You have Parkinson's disease at a moderate stage.You have been diagnosed with a current major depressive episode using the MINI International Neuropsychiatric Interview, Version 6.You have a score of 22 or higher on a test that measures how severe your depression is.You are approved by a psychiatrist and an anaesthesiologist to receive convulsive therapy.If you are taking antidepressant medication, you must be willing to continue taking the same medication during the study.Meet the safety criteria for the study.You have been diagnosed with a serious memory and thinking disorder other than Parkinson's disease, or your Montreal Cognitive Assessment score is less than 21.
Research Study Groups:
This trial has the following groups:- Group 1: Magnetic Seizure Therapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the total number of patients participating in this research endeavor?
"Affirmative. Clinicaltrials.gov's records confirm that this trial, which was initially published on September 20th 2021 is actively recruiting participants. A total of 20 volunteers are required to participate in the study at a single medical site."
Answered by AI
Are participants invited to join the trial at this point in time?
"The clinical trial, which was initialised on the 20th of September 2021, is presently recruiting patients according to information stored on ClinicalTrials.gov. This data has been recently updated as of the 29th of September 2021."
Answered by AI
Share this study with friends
Copy Link
Messenger